Back to results
US 2012/0258118 A1Published application
Antibody therapeutics with local activity in the digestive tract
OwnerBarbara S. Fox, Douglas C. Staffordinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerBarbara S. Fox, Douglas C. Staffordinventors
Estimating the term…
This invention provides methods and compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been shown to be necessary for clinical benefit following systemic administration of antibody. This invention further describes therapeutic compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been associated with adverse events and systemic immunosuppression following systemic administration of antibody.
A method of treating inflammatory bowel disease comprising administering a polyclonal, milk-derived, anti-TNF antibody to the digestive tract wherein the peak level of anti-TNF antibody in the patient's serum after administration of the anti-TNF antibody is less than about 1 μg/ml.
A composition comprising a bovine derived, polyclonal, anti-TNF antibody wherein the antibody is present in the composition in an amount effective to topically treat inflammatory bowel disease wherein upon administration of the composition, the peak level of anti-TNF antibody in the patient's serum after administration of the anti-TNF antibody is less than 1 μg/ml.
The use of a composition comprising a bovine derived, polyclonal, anti-TNF antibody for topical treatment of a patient with inflammatory bowel disease wherein the peak level of antibody detectable in a patient's serum after administration of the anti-TNF antibody is less than about 1 μg/ml.
A composition comprising a bovine derived, polyclonal antibody specific to an anti-inflammatory cytokine wherein the antibody is present in the composition in an amount effective to topically treat inflammation of the digestive tract of a patient, wherein the peak level of antibody detectable in a patient's serum after administration of the antibody is less than 1 μg/ml.
A method of treating inflammation of the digestive tract in a patient comprising administering to the patient's digestive tract, an antibody specific for an inflammatory cytokine, wherein the peak level of antibody in the patient's serum after administration of the antibody is less than 1 μg/ml.
The use of a composition comprising a bovine derived, polyclonal antibody specific to an anti-inflammatory cytokine for topical treatment of inflammation of the gastrointestinal tract of a patient, wherein the peak level of antibody detectable in a patient's serum after administration of the antibody is less than 1 μg/ml.
A method for treating mucositis comprising administering a polyclonal, milk-derived, anti-TNF antibody to the gastrointestinal (GI) tract wherein the peak level of anti-TNF antibody in the patient's serum after administration of the anti-TNF antibody is less than 1 μg/ml.
A method of delivering an antibody to the digestive tract comprising contacting the antibody with the digestive tract wherein the mucosal barrier of the patient's digestive tract is optionally compromised such that it is permeable to the antibody, wherein the antibody is specific to biological targets on the luminal surface of the digestive tract or below the mucosal barrier of the digestive tract, and wherein the peak level of antibody in the patient's serum after administration of the antibody is less than about 1 μg/ml.
Dependencies are inferred from the claim text.